Kaitlin Kestenberg compensation by year
ADMA BIOLOGICS Summary Compensation Table · all 2 fiscal years held| Component | FY2024 | FY2025 |
|---|---|---|
| Salary | $433,137 | $575,000 |
| Bonus | $0 | $0 |
| Stock awards | $1,257,773 | $1,249,989 |
| Option awards | $1,266,439 | $1,249,999 |
| Non-equity incentive | $345,000 | $359,375 |
| Pension and deferred compensation | $0 | $0 |
| All other | $37,671 | $54,284 |
| Total | $3,340,020 | $3,488,647 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ADMA BIOLOGICS, INC. DEF 14A filed April 15, 2026, accession 0001140361-26-014799, and prior-year filings.
How this page was built: the ADMA BIOLOGICS, INC. filed document, accession 0001140361-26-014799. Every figure is read from that document and cited to the page and table it appears in. Filed April 15, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 144,240 | $2,630,938 | — |
| RSU | 77,784 | $1,418,780 | — |
| RSU | 47,500 | $866,400 | — |
| RSU | 15,000 | $273,600 | — |
| RSU | 10,000 | $182,400 | — |
| Option | 175,192 | — | $6.54 |
| Option | 116,479 | — | $16.07 |
Per the Outstanding Equity Awards at Fiscal Year-End table in ADMA BIOLOGICS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments ADMA BIOLOGICS discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and involuntary termination | $718,750 | $7,674,191 | $36,000 | $8,860,191 |
| Involuntary termination without cause | $575,000 | $0 | $36,000 | $611,000 |
Per the Potential Payments Upon Termination or Change in Control table in ADMA BIOLOGICS, INC.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
ADMA BIOLOGICS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Adam Grossman | President, Chief Executive Officer and Director | $10,237,326 |
| Kaitlin Kestenberg · this page | Chief Operating Officer & Senior Vice President, Compliance | $3,488,647 |
| Brad Tade | Former Executive Vice President and Chief Financial Officer | $2,823,630 |
| Paul Kohler | Current Chief Financial Officer and Treasurer | $2,296,949 |
Kaitlin Kestenberg's compensation dossier, ADMA BIOLOGICS
You have read Kaitlin Kestenberg's totals and holdings. The dossier adds each equity grant ADMA BIOLOGICS disclosed for Kaitlin Kestenberg and ADMA BIOLOGICS's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full ADMA BIOLOGICS compensation record
free company briefThis page is one person within ADMA BIOLOGICS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the ADMA BIOLOGICS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order ADMA BIOLOGICS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ADMA BIOLOGICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.